During preformulation screening of gliclazide for immediate-release solid oral dosage forms, wet granulation is selected after direct compression trials show capping at compaction pressures above 8–12 kN and unacceptable segregation in low-dose blends. Gliclazide behaves as a low-solubility weak acid with pKa near 5.8, which makes pH-adjusted dissolution media and micronization necessary to achieve content uniformity and release control in 40 mg and 80 mg tablets. Industry compliance for commercial immediate-release tablets requires dissolution testing under Ph. Eur. 2.9.3 and USP <711> using Apparatus II at 50 rpm in phosphate buffer pH 7.4, uniformity of dosage units per USP <905> or Ph. Eur. 2.9.40, friability per Ph. Eur. 2.9.7, and control of degradation products and residual solvents under ICH Q3B(R2) and ICH Q3C(R8). Formulation addition ratios reported in pilot-scale development work range from 8% to 25% w/w for gliclazide when producing 40 mg or 80 mg tablets; intragranular crospovidone is used at 2–4% w/w, PVP K30 binder at 1–3% w/w, and magnesium stearate at 0.25–0.75% w/w. Downstream production on a high-shear granulator with bowl capacity 150–600 L uses purified water or a 5% w/w PVP solution as granulating fluid, with impeller tip speed 3–7 m/s, chopper speed 1500–3000 rpm, and endpoint controlled by impeller power consumption and wet mass torque; the wet granules are milled through a 1.0 mm screen, dried in a fluid bed at inlet air 55–70°C to loss-on-drying 1.5–2.5% w/w, blended in a V-blender or bin blender for 5–10 min, and compressed on a rotary tablet press to hardness 60–100 N and friability below 0.8%. Terminal finished dosage types are biconvex scored 40 mg and 80 mg immediate-release tablets, with release acceptance criteria linked to the pharmacopoeial tablet monograph and stability data generated at 25°C/60% RH and 40°C/75% RH according to ICH Q1A(R2).

What Governs Gel-Layer Formation in Prolonged-Release Matrix Systems Containing Gliclazide?

Modified-release tablets containing 30 mg or 60 mg of gliclazide rely on hydrophilic matrix polymer hydration rather than functional film coating to extend release over 12–24 h. Compliance for modified-release solid oral dosage forms requires multi-point dissolution profiling under Ph. Eur. 2.9.3 and USP <711> using the apparatus and rotation speed specified in the product monograph, stability testing per ICH Q1A(R2) with dissolution as a critical quality attribute, and uniformity of dosage units per USP <905> or Ph. Eur. 2.9.40. Formulation addition ratios in development studies use hypromellose K4M or K100LV at 8–30% w/w, gliclazide at 10–15% w/w for 60 mg tablets, lactose monohydrate or calcium hydrogen phosphate dihydrate filler at 40–70% w/w, and magnesium stearate at 0.5–1.0% w/w; the filler type and particle size distribution are adjusted so that the gel layer forms uniformly on the tablet surface. The downstream process is typically direct compression after dry blending, using a rotary tablet press with pre-compression 3–8 kN and main compression 15–25 kN; production-scale bin blender trials show that segregation of hypromellose and micronized gliclazide shifts release rate, so controlled addition order, matched particle size, and blender fill levels of 50–70% at 20–25 rpm for 10–15 min are required. Terminal finished dosage types are round biconvex prolonged-release tablets of 30 mg and 60 mg, with identity by infrared or near-infrared spectroscopy, assay by HPLC, and release-rate testing across multiple time points; alcohol dose-dumping studies may be required by regulatory authorities when matrix composition changes are proposed, and packaging in aluminium-aluminium blister units is used to limit moisture-induced alteration of polymer hydration.

Bilayer Compression Interface Dynamics for Metformin HCl Co-Formulations

Because metformin hydrochloride contributes both high aqueous solubility and a high mass fraction in fixed-dose combinations, bilayer compression or monolithic granulation is used to pair gliclazide at 40 mg or 80 mg with metformin HCl at 500 mg or 1000 mg. Compliance standards include USP <905> for uniformity of dosage units, USP <711> for dissolution using separate analytical methods for each active ingredient, ICH Q3B(R2) for degradation products including metformin impurities, and FDA 21 CFR 211.110 for in-process blend uniformity and sampling plans. In bilayer formulations, the gliclazide layer commonly contains 5–10% w/w API, while the metformin layer contains 70–90% w/w metformin HCl with croscarmellose sodium at 1–3% w/w and magnesium stearate at 0.5–1.0% w/w; the metformin layer thickness often exceeds the gliclazide layer thickness by 2–5 times depending on dose and tablet tooling dimensions. Downstream processing on a bilayer rotary tablet press with D-tooling requires pre-compression of the first layer at 2–6 kN and final compression at 15–40 kN, with turret speed limited to 20–45 rpm to control lamination at the interface; metformin's static charge in low-humidity feed frames causes sticking and weight variation, so closed-loop feed control and 35–50% RH conditioning are used, and vacuum-assisted die filling is applied where available. The terminal finished dosage types are film-coated bilayer tablets intended for twice-daily administration, with hardness 100–180 N, friability below 0.5% after coating, and in vitro release targets derived from the corresponding monographs; published data for specific commercial formulations are limited, but the processing window is consistent with development literature for high-dose metformin fixed-dose combinations.

Where roller compaction is selected over wet granulation to avoid exposing gliclazide to aqueous granulating fluid and subsequent drying heat, capsule formulations provide a low-shear alternative for 40 mg or 80 mg doses. Commercial standards for hard capsule products include the pharmacopoeial capsule monograph, USP <701> or Ph. Eur. 2.9.1 disintegration, USP <711> or Ph. Eur. 2.9.3 dissolution, and ICH Q3D(R2) elemental impurity control with oral permitted daily exposure derived from the API, excipients, and capsule shell. Formulation addition ratios in dry-granulated capsules typically use gliclazide at 5–15% w/w, microcrystalline cellulose at 30–60% w/w, lactose monohydrate at 20–40% w/w, crospovidone at 2–4% w/w, and magnesium stearate at 0.5–1.5% w/w; because gliclazide is poorly compressible, the API is pre-blended with filler and reintroduced as milled granules to improve flow and encapsulation weight consistency. Downstream production runs on a roller compactor with roll pressure 20–80 kN, gap 1–3 mm, and ribbon density controlled to 1.2–1.4 g/cm³; milled granules are sieved to 0.8–1.6 mm, lubricated for 2–5 min, and filled into hard gelatin or HPMC capsules using a dosator or tamping-pin encapsulation machine at 30,000–100,000 capsules/h. Terminal finished dosage types are size 3 or 4 hard capsules containing 40 mg or 80 mg gliclazide, with moisture content maintained below 3% w/w during storage to prevent shell cross-linking and dissolution slowdown, as observed in stability studies at 40°C/75% RH.

When Gliclazide Is Delivered as Dispersible Granules for Dysphagia Populations

Granule formulations for oral suspension are used when patients cannot swallow tablets; gliclazide's low aqueous solubility requires micronized API and wetting agent addition to achieve adequate dispersion and avoid floating or clumping after reconstitution. Compliance standards include Ph. Eur. 2.9.35 particle-size distribution by sieving for powders and granules, Ph. Eur. 2.9.5 uniformity of mass of single-dose preparations, USP <905> for content uniformity, and ICH Q6A decision trees for dissolution or disintegration; if prepared extemporaneously in hospital pharmacy, USP <795> nonsterile compounding requirements and FDA 503A/503B frameworks apply in the United States. Addition ratios in single-dose sachets delivering 20–60 mg gliclazide typically use mannitol or xylitol at 30–60% w/w as sweetening bulking agent, xanthan gum or hypromellose at 0.1–1.0% w/w as suspending viscosity modifier, sodium lauryl sulfate at 0.05–0.2% w/w as wetting agent, citric acid at 0.2–0.5% w/w for pH adjustment, and colloidal silicon dioxide at 0.1–0.5% w/w as glidant prior to sachet filling. Downstream production uses top-spray fluid-bed granulation with a 5% PVP K30 or maltodextrin binder solution sprayed at 10–25 g/min per kg of substrate, inlet air 55–70°C, product temperature 25–35°C, and final granule D50 150–400 µm; the dried granules are sieved, blended, and filled into stick-pack or sachet equipment at low relative humidity below 40% RH to prevent flow instability and moisture pick-up. Terminal finished dosage types are unit-dose sachets containing powder for oral suspension, with reconstitution in 30–50 mL water achieving a uniformly dispersed suspension within 60 seconds in development testing; the dosage form is distinguished from conventional tablets by requiring patient-ready labeling for dispersion and immediate administration.

Parenteral Gliclazide Solubilisation and Sterility Constraints in Investigational Dosage Forms

Although no commercial parenteral monograph exists for gliclazide, development-grade injectable formulations require solubility enhancement and sterility assurance rather than tablet-scale blending. Relevant compliance standards include the Ph. Eur. monograph on Parenteral Preparations (0520), USP <1> Injections and Implanted Drug Products, ICH Q3C(R8) for residual solvents used in co-solvent systems, ICH Q3D(R2) for elemental impurities by the parenteral route, and EU GMP Annex 1 for aseptic processing. Published data for this specific configuration are limited, but feasibility work has evaluated gliclazide at 1–10 mg/mL using co-solvent systems containing PEG 300 or PEG 400, propylene glycol, and water at pH 7.0–9.0, or sulfobutylether-β-cyclodextrin inclusion at molar ratios between 1:5 and 1:10. Downstream processing for such investigational products requires aseptic filtration through 0.22 µm PVDF or PES membranes if fully dissolved, or cool processing for nanodispersions; terminal steam sterilisation at 121°C for 15 min is generally avoided unless forced-degradation studies prove hydrolytic stability, because sulfonylurea compounds can degrade under prolonged heat-moisture stress. Terminal dosage forms under evaluation include lyophilized powder for reconstitution, solution for intravenous or intramuscular administration in clinical trial settings, and sterile nanodispersion vials; each requires particulate matter testing per Ph. Eur. 2.9.19 and USP <790>, bacterial endotoxin testing per Ph. Eur. 2.6.14 or USP <85>, sterility testing per Ph. Eur. 2.6.1 or USP <71>, and container closure integrity testing per USP <1207>.